Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Instil Bio Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody Today 6:00 EDT From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update May 10, 2024 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Strategic Update January 16, 2024 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split December 05, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting November 06, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference June 26, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update May 11, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update March 31, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site January 31, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer January 09, 2023 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce December 08, 2022 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 14, 2022 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting November 08, 2022 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing October 31, 2022 From Instil Bio Via GlobeNewswire Tickers TIL Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer October 18, 2022 From Instil Bio Via GlobeNewswire Tickers TIL Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.